medical guideline
首页
中医/中西医结合指南
肿瘤学指南
泌尿外科指南
关于我们
郑重声明
联系我们
首页
肿瘤学指南
检索结果
人体系统
运动
骨肿瘤
软组织肿瘤
骨与软组织肿瘤
硬纤维瘤
骶尾部畸胎瘤
神经
中枢神经系统肿瘤
胶质细胞瘤
前庭神经鞘瘤
神经内分泌肿瘤
神经细胞瘤
嗜铬细胞瘤和副神经节瘤
副神经节瘤
星形胶质细胞瘤和少突胶质细胞瘤
弥漫性胶质瘤
神经纤维瘤
内分泌
神经内分泌肿瘤
甲状腺肿瘤
垂体肿瘤
肾上腺肿瘤
胸腺肿瘤
甲状旁腺肿瘤
循环
心脏肿瘤
淋巴瘤
骨髓瘤
白血病
血液肿瘤
血管瘤
呼吸
肺癌
鼻咽癌
喉部肿瘤
下咽癌
鼻腔和副鼻窦癌
呼吸道肿瘤
鼻颅咽管瘤
淋巴管肌瘤
消化
胰腺肿瘤
口腔癌
肛门癌
口咽癌
胆囊癌
胆管肿瘤
直肠癌
结肠癌
胃癌
小肠癌
肝癌
大肠肿瘤
唾液腺癌
阑尾肿瘤
食管肿瘤
肝肿瘤
结直肠肿瘤
肝胆癌
食管胃肿瘤
胃肠道肿瘤
消化道肿瘤
壶腹肿瘤
泌尿
膀胱肿瘤
肾癌
尿路上皮癌
泌尿生殖肿瘤
脐尿管癌
肾血管平滑肌脂肪瘤
生殖
女性
子宫肿瘤
卵巢肿瘤
乳腺肿瘤
阴道肿瘤
外阴癌
妊娠滋养细胞肿瘤
妇科肿瘤
男性
前列腺肿瘤
睾丸肿瘤
阴茎癌
男性乳腺肿瘤
泌尿生殖肿瘤
输卵管癌
性索间质瘤
其他
症状管理
皮肤肿瘤
腹膜肿瘤
实体瘤
老年肿瘤
儿童/青少年肿瘤
头颈部肿瘤
治疗方案
诊断/检测/评估方法
预防和筛查
COVID-19大流行癌症患者相关指导建议
黑色素瘤
康复营养
生育能力
体力活动
心理健康
胸部肿瘤
长期监测
Cowden综合征
转诊
遗传性癌症综合征
癌症患者其他类问题管理
寡转移性疾病
基因测序
易感基因变异的分类
外科肿瘤
罕见癌症
不明原因癌症
纤维瘤
腹部肿瘤
人类微生物组与癌变
检索结果
按关键字
按标题
按关键词
按摘要
按作者
按期刊
按发表年份
共搜索到
67条
与
Patients
有关的结果
Individualizing Surveillance Mammography for Older Patients after Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement
2021年 发布于
JAMA Oncology
7卷 第4期
所属人体系统：
生殖
|
乳腺肿瘤
International Society of Geriatric Oncology
Early-stage Breast Cancer
Older
Patients
Treatment
Individualizing Surveillance Mammography
Consensus
指南简介
原文链接
Mantle Cell Lymphoma(Guideline for Patients)
2021年 发布于
National Comprehensive Cancer Network
卷 第期
所属人体系统：
循环
|
淋巴瘤
National Comprehensive Cancer Network
Patients
Mantle Cell
Lymphoma
testing
treatment
指南简介
原文链接
Primary Central Nervous System Lymphoma(Guideline for Patients)
2021年 发布于
National Comprehensive Cancer Network
卷 第期
所属人体系统：
循环
|
淋巴瘤
National Comprehensive Cancer Network
Patients
Central Nervous System
Lymphoma
treatment
指南简介
原文链接
Hodgkin Lymphoma(Guideline for Patients)
2021年 发布于
National Comprehensive Cancer Network
卷 第期
所属人体系统：
循环
|
淋巴瘤
National Comprehensive Cancer Network
Patients
Hodgkin
Lymphoma
testing
treatment
指南简介
原文链接
Mycosis Fungoides/Sézary Syndrome(Guideline for Patients)
2021年 发布于
National Comprehensive Cancer Network
卷 第期
所属人体系统：
循环
|
淋巴瘤
National Comprehensive Cancer Network
Patients
Mycosis Fungoides
Sézary Syndrome
testing
treatment
staging
指南简介
原文链接
Multiple Myeloma(Guideline for Patients)
2021年 发布于
National Comprehensive Cancer Network
卷 第期
所属人体系统：
循环
|
骨髓瘤
National Comprehensive Cancer Network
Patients
Multiple Myeloma
testing
treatment
指南简介
原文链接
Acute Lymphoblastic Leukemia (pediatric)(Guideline for Patients)
2021年 发布于
National Comprehensive Cancer Network
卷 第期
所属人体系统：
循环
|
白血病
National Comprehensive Cancer Network
Patients
Acute
Lymphoblastic Leukemia
pediatric
testing
treatment
指南简介
原文链接
Malignant Pleural Mesothelioma(Guideline for Patients)
2021年 发布于
National Comprehensive Cancer Network
卷 第期
所属人体系统：
其他
|
胸部肿瘤
National Comprehensive Cancer Network
Patients
Malignant
Pleural Mesothelioma
testing
treatment
指南简介
原文链接
The 2020 Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
2021年 发布于
Journal of Gynecologic Oncology
32卷 第2期
所属人体系统：
生殖
|
卵巢肿瘤
Japan Society of Gynecologic Oncology
The Fifth Edition of the Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer Was Published in 2020. the Guidelines Contain 6 Chapters-namely
(1) Overview of the Guidelines
(2) Epithelial Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(3) Recurrent Epithelial Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(4) Borderline Epithelial Tumors of the Ovary
(5) Malignant Germ Cell Tumors of the Ovary
and (6) Malignant Sex Cord-stromal Tumors. Furthermore
the Guidelines Comprise 5 Algorithms-namely
(1) Initial Treatment for Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(2) Treatment for Recurrent Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(3) Initial Treatment for Borderline Epithelial Ovarian Tumor
(4) Treatment for Malignant Germ Cell Tumor
and (5) Treatment for Sex Cord-stromal Tumor. Major Changes in the New Edition Include the Following: (1) Revision of the Title to "guidelines for the Treatment of Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer"
(2) Involvement of
Patients
and General (male/female) Participants in Addition to Physicians
Pharmacists
and Nurses
(3) Clinical Questions (CQs) in the PICO Format
(4) Change in the Expression of Grades of Recommendation and Level of Evidence in Accordance with the GRADE System
(5) Introduction of the Idea of a Body of Evidence
(6) Categorization of References According to Research Design
(7) Performance of Systematic Reviews and Meta-analysis for Three CQs
and (8) Voting for Each CQ/recommendation and Description of the Consensus.
指南简介
原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma
2021年 发布于
Current Oncology
28卷 第2期
所属人体系统：
生殖
|
卵巢肿瘤
Ontario Health (Cancer Care Ontario)
Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II
III
Or IV Epithelial Ovary
Fallopian Tube
Or Primary Peritoneal Carcinoma Including All Histological Types.
Methods: Consistent with the Program in Evidence-based Program's Standardized Approach
MEDLINE
EMBASE
PubMed
Cochrane Library
and PROSPERO (the International Prospective Register of Systematic Reviews) Databases
and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers.
Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall
Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy
We Recommended Olaparib (Recommendation)
Niraparib (Weak Recommendation)
Veliparib (Weak Recommendation)
and Bevacizumab (Weak Recommendation) for Certain
Patients
with Newly Diagnosed Stage III-IV Epithelial Ovarian
Fallopian Tube
Or Primary Peritoneal Carcinoma
Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available
the Recommendations Will Be Updated as Soon as Possible.
指南简介
原文链接
Soft Tissue Sarcoma(Guideline for Patients)
2021年 发布于
National Comprehensive Cancer Network
卷 第期
所属人体系统：
运动
|
软组织肿瘤
National Comprehensive Cancer Network
Patients
Soft Tissue Sarcoma
testing
treatment
指南简介
原文链接
The 2020 Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
2021年 发布于
Journal of Gynecologic Oncology
32卷 第2期
所属人体系统：
生殖
|
输卵管癌
Japan Society of Gynecologic Oncology
The Fifth Edition of the Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer Was Published in 2020. the Guidelines Contain 6 Chapters-namely
(1) Overview of the Guidelines
(2) Epithelial Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(3) Recurrent Epithelial Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(4) Borderline Epithelial Tumors of the Ovary
(5) Malignant Germ Cell Tumors of the Ovary
and (6) Malignant Sex Cord-stromal Tumors. Furthermore
the Guidelines Comprise 5 Algorithms-namely
(1) Initial Treatment for Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(2) Treatment for Recurrent Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(3) Initial Treatment for Borderline Epithelial Ovarian Tumor
(4) Treatment for Malignant Germ Cell Tumor
and (5) Treatment for Sex Cord-stromal Tumor. Major Changes in the New Edition Include the Following: (1) Revision of the Title to "guidelines for the Treatment of Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer"
(2) Involvement of
Patients
and General (male/female) Participants in Addition to Physicians
Pharmacists
and Nurses
(3) Clinical Questions (CQs) in the PICO Format
(4) Change in the Expression of Grades of Recommendation and Level of Evidence in Accordance with the GRADE System
(5) Introduction of the Idea of a Body of Evidence
(6) Categorization of References According to Research Design
(7) Performance of Systematic Reviews and Meta-analysis for Three CQs
and (8) Voting for Each CQ/recommendation and Description of the Consensus.
指南简介
原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma
2021年 发布于
Current Oncology
28卷 第2期
所属人体系统：
生殖
|
输卵管癌
Ontario Health (Cancer Care Ontario)
Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II
III
Or IV Epithelial Ovary
Fallopian Tube
Or Primary Peritoneal Carcinoma Including All Histological Types.
Methods: Consistent with the Program in Evidence-based Program's Standardized Approach
MEDLINE
EMBASE
PubMed
Cochrane Library
and PROSPERO (the International Prospective Register of Systematic Reviews) Databases
and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers.
Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall
Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy
We Recommended Olaparib (Recommendation)
Niraparib (Weak Recommendation)
Veliparib (Weak Recommendation)
and Bevacizumab (Weak Recommendation) for Certain
Patients
with Newly Diagnosed Stage III-IV Epithelial Ovarian
Fallopian Tube
Or Primary Peritoneal Carcinoma
Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available
the Recommendations Will Be Updated as Soon as Possible.
指南简介
原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma
2021年 发布于
Current Oncology
28卷 第2期
所属人体系统：
其他
|
腹膜肿瘤
Ontario Health (Cancer Care Ontario)
Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II
III
Or IV Epithelial Ovary
Fallopian Tube
Or Primary Peritoneal Carcinoma Including All Histological Types.
Methods: Consistent with the Program in Evidence-based Program's Standardized Approach
MEDLINE
EMBASE
PubMed
Cochrane Library
and PROSPERO (the International Prospective Register of Systematic Reviews) Databases
and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers.
Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall
Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy
We Recommended Olaparib (Recommendation)
Niraparib (Weak Recommendation)
Veliparib (Weak Recommendation)
and Bevacizumab (Weak Recommendation) for Certain
Patients
with Newly Diagnosed Stage III-IV Epithelial Ovarian
Fallopian Tube
Or Primary Peritoneal Carcinoma
Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available
the Recommendations Will Be Updated as Soon as Possible.
指南简介
原文链接
The 2020 Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
2021年 发布于
Journal of Gynecologic Oncology
32卷 第2期
所属人体系统：
其他
|
腹膜肿瘤
Japan Society of Gynecologic Oncology
The Fifth Edition of the Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer Was Published in 2020. the Guidelines Contain 6 Chapters-namely
(1) Overview of the Guidelines
(2) Epithelial Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(3) Recurrent Epithelial Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(4) Borderline Epithelial Tumors of the Ovary
(5) Malignant Germ Cell Tumors of the Ovary
and (6) Malignant Sex Cord-stromal Tumors. Furthermore
the Guidelines Comprise 5 Algorithms-namely
(1) Initial Treatment for Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(2) Treatment for Recurrent Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(3) Initial Treatment for Borderline Epithelial Ovarian Tumor
(4) Treatment for Malignant Germ Cell Tumor
and (5) Treatment for Sex Cord-stromal Tumor. Major Changes in the New Edition Include the Following: (1) Revision of the Title to "guidelines for the Treatment of Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer"
(2) Involvement of
Patients
and General (male/female) Participants in Addition to Physicians
Pharmacists
and Nurses
(3) Clinical Questions (CQs) in the PICO Format
(4) Change in the Expression of Grades of Recommendation and Level of Evidence in Accordance with the GRADE System
(5) Introduction of the Idea of a Body of Evidence
(6) Categorization of References According to Research Design
(7) Performance of Systematic Reviews and Meta-analysis for Three CQs
and (8) Voting for Each CQ/recommendation and Description of the Consensus.
指南简介
原文链接
Distress During Cancer Care(Guideline for Patients)
2021年 发布于
National Comprehensive Cancer Network
卷 第期
所属人体系统：
其他
|
心理健康
National Comprehensive Cancer Network
Patients
Distress
Cancer
management
指南简介
原文链接
Squamous Cell Skin Cancer(Guideline for Patients)
2021年 发布于
National Comprehensive Cancer Network
卷 第期
所属人体系统：
其他
|
皮肤肿瘤
National Comprehensive Cancer Network
Patients
Squamous Cell
Skin Cancer
treatment
指南简介
原文链接
8th European Conference on Infections in Leukaemia: 2020 Guidelines for the Use of Antibiotics in Paediatric Patients with Cancer Or Post-haematopoietic Cell Transplantation
2021年 发布于
The Lancet. Oncology
卷 第期
所属人体系统：
其他
|
治疗方案
A Paediatric Group at the 8th European Conference on Infections in Leukaemia (ECIL-8)
Paediatric
Patients
Cancer
Haematopoietic Cell Transplantation
Antibiotics
Guideline
指南简介
原文链接
8th European Conference on Infections in Leukaemia: 2020 Guidelines for the Diagnosis, Prevention, and Treatment of Invasive Fungal Diseases in Paediatric Patients with Cancer Or Post-haematopoietic Cell Transplantation
2021年 发布于
The Lancet. Oncology
卷 第期
所属人体系统：
其他
|
症状管理
8th European Conference on Infections in Leukaemia
Cancer
Haematopoietic Cell Transplantation
Paediatric
Patients
Invasive Fungal Diseases
Diagnosis
Prevention
Treatment
Guideline
指南简介
原文链接
Options for Prevention and Management of Menstrual Bleeding in Adolescent Patients Undergoing Cancer Treatment: ACOG Committee Opinion, Number 817
2021年 发布于
Obstet Gynecol
137卷 第1期
所属人体系统：
其他
|
症状管理
American College of Obstetricians and Gynecologists’ Committee on Adolescent Health Care
Cancer
Adolescent
Patients
Menstrual Bleeding
Prevention
Management
Guideline
指南简介
原文链接
首页
1
2
3
4
下一页
尾页
共67条，每页显示
20条
50条
100条
跳转至第
页
确定
